Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009 Jul; 8(7):1867-77.
View in:
PubMed
subject areas
Animals
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
Bevacizumab
Biomarkers, Tumor
Blotting, Western
Brain Neoplasms
Cell Proliferation
DNA Damage
Drug Synergism
Female
Glioma
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
Immunoenzyme Techniques
Luciferases
Mice
Mice, Nude
Neovascularization, Pathologic
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger
Topotecan
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
authors with profiles
Bradley Carl Gehrs